About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All
2024
2023
2022
2021
2020
29
Dec 2022
16:30 E.S.T.
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
Read more
28
Dec 2022
12:59 E.S.T.
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
Read more
22
Dec 2022
16:30 E.S.T.
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
Read more
13
Dec 2022
07:30 E.S.T.
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
Read more
01
Dec 2022
16:30 E.S.T.
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
Read more
10
Nov 2022
09:05 E.S.T.
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
Read more
1
2
3
Next